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Introduction: Patients with acute respiratory failure requiring respiratory support with invasive mechanical
ventilation while awaiting lung transplantation are at a high risk of death. Extracorporeal membrane oxygenation
(ECMO) has been proposed as an alternative bridging strategy to mechanical ventilation. The aim of this study was
to assess the current evidence regarding how the ECMO bridge influences patients’ survival and length of hospital
stay.
Methods: We performed a systematic review by searching PubMed, EMBASE and the bibliographies of retrieved
articles. Three reviewers independently screened citation titles and abstracts and agreement was reached by
consensus. We selected studies enrolling patients who received ECMO with the intention to bridge lung transplant.
We included randomized controlled trials (RCTs), case–control studies and case series with ten or more patients.
Outcomes of interest included survival and length of hospital stay. Quantitative data summaries were made when
feasible.
Results: We identified 82 studies, of which 14 were included in the final analysis. All 14 were retrospective studies
which enrolled 441 patients in total. Because of the broad heterogeneity among the studies we did not perform a
meta-analysis. The mortality rate of patients on ECMO before lung transplant and the one-year survival ranged from
10% to 50% and 50% to 90%, respectively. The intensive care and hospital length of stay ranged between a median
of 15 to 47 days and 22 to 47 days, respectively. There was a general paucity of high-quality data and significant
heterogeneity among studies in the enrolled patients and technology used, which confounded analysis.
Conclusions: In most of the studies, patients on ECMO while awaiting lung transplantation also received invasive
mechanical ventilation. Therefore, whether ECMO as an alternative, rather than an adjunction, to invasive
mechanical ventilation is a better bridging strategy to lung transplantation still remains an unresolved issue. ECMO
support as a bridge for these patients could provide acceptable one-year survival. Future studies are needed to
investigate ECMO as part of an algorithm of care for patients with end-stage lung disease.Introduction
Lung transplant is considered an established treatment for
patients with end-stage chronic respiratory failure [1]. Since
the first successful report in 1983 by Cooper and colleagues
[2], more than 30,000 lung transplants have been done
worldwide [3]. The significantly larger number of candi-
dates than available organs explains the long waiting times
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unless otherwise stated.[1,4-6]. Contributing to this high mortality rate is also the
lack of efficacious and safe means of artificial respiratory
support for patients awaiting the transplant once they de-
velop acute respiratory failure with refractory hypoxemia
and hypercapnia [4,7]. Mechanical ventilation per se can ag-
gravate acute respiratory failure and hemodynamic instabil-
ity, increasing the risk of ventilator-associated pneumonia
and ventilator-induced lung injury [7-10]. Mechanically
ventilated pre-transplant patients have been reported to
have significantly higher post-transplant mortality rates
than non-ventilated patients [11,12].
More than three decades ago, extracorporeal mem-
brane oxygenation (ECMO) was introduced to manage
patients on the lung transplant waiting list who weretral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ical ventilation [4,13]. The first report of ECMO as a
feasible bridging strategy to transplantation goes back to
1975: the patient survived transplantation but died
shortly after from complications of infection [14]. After
a randomized trial that suggested that ECMO was asso-
ciated with a worse outcome than mechanical ventilation
in patients with acute respiratory failure [15], ECMO as
a bridge to lung transplant fell into disuse [4].
More recently, however, thanks to improvements in
technology, safety profile and manageability of extracor-
poreal life support strategies [16,17], ECMO has been
reintroduced in some centers as an option for patients
with severe respiratory failure awaiting lung transplant
[4,10,13,18-22]. The number of lung transplant candidates
who could benefit from ECMO is now significantly larger
[13,19,20,22]. A report by the United Network of Organ
Sharing (UNOS) showed that, despite its complexity and
side effects, the use of ECMO as a bridge to lung trans-
plant has risen by 150% in the two last years compared to
the previous decades (1970 to 2010) [4]. However, given
the small numbers of transplantable lungs, bridging lung-
transplant candidates on ECMO has raised ethical con-
cerns about the risk of potentially selecting for transplant-
ation, very severely ill patients with the risk of poor post-
transplant outcome. Instead, according to the lung alloca-
tion score (LAS) system, organs should be allocated to pa-
tients who have the greatest need, such as those on
ECMO, but who are also likely to benefit most from the
transplant [5,6,23,24].
In this perspective, new advances have demonstrated
the potential of ECMO as an alternative to mechanical
ventilation in awake, spontaneously breathing patients.
With awake-ECMO patients preserve their muscle tone,
with greater possibility of early mobilization and partici-
pation in intensive physical therapy, thus improving
their condition before a lung transplant and making for
a better post-transplant outcome [20,25-29].
Given the lack of definitive data on the efficacy of
ECMO as bridge to lung transplantation, and the conse-
quent lack of a clear consensus on this strategy [6], we
conducted a systematic review to assess the current evi-
dence on the use of ECMO in patients with advanced re-
spiratory failure awaiting lung transplant.
Materials and methods
Search strategy and selection of studies
Our search used the statement - preferred reporting items
for systematic reviews and meta-analyses (PRISMA) - as a
guide [30]. We made a computerized search of MED-
LINE/PubMED and EMBASE databases from January
2000 to June 2014. Our search was limited to studies on
humans and adults. We limited the selection to studies
written in English, French, German or Spanish. We usedthe following search keywords and terms: “preoperative
extracorporeal membrane oxygenation” OR “preopera-
tive ECMO” AND “lung transplantation”, “extracorpor-
eal membrane oxygenation” OR “ECMO” AND “bridge
to lung transplantation”, “ambulatory extracorporeal
membrane oxygenation” OR “ambulatory ECMO” AND
“lung transplantation”.
Three reviewers (DC, SC and SF) independently
screened citation titles and abstracts. We looked through
the references of all articles retrieved and reviewed the
articles to identify additional potentially eligible studies.
In case of disagreement the authors reviewed the article
in question together until they reached a consensus. We
deleted duplicate papers. All potentially eligible papers
were retrieved in full and assessed to confirm eligibility.
We screened studies for relevance that enrolled pa-
tients awaiting lung transplant who were admitted to
ICU to receive ECMO support as a bridging procedure,
including veno-venous approach and veno-arterial sup-
port. We excluded studies that enrolled patients treated
with pump-free extracorporeal interventional lung-assist
devices. We included studies enrolling at least ten pa-
tients on ECMO bridging. Data were abstracted in dupli-
cate by two reviewers (SC and SF) and any discrepancies
were solved by discussion.
The following information was collected in a datasheet:
publication (first author’s name, year, journal), study de-
sign, number of enrolled patients on ECMO bridge, num-
ber of patients who died while awaiting transplant, type of
ECMO support, timing of ECMO bridge, outcomes, sur-
vival after lung transplant.
Assessment of methodological quality
Two authors (SC and SF) independently assessed the
methodological quality of the studies. They employed crit-
ical appraisal skills program (CASP) tools using the CASP
checklist for case-control studies [31].
Results
Study selection and characteristics
The initial search strategy identified 82 potentially eli-
gible studies (Figure 1); 69 studies were excluded for the
following reasons: 5 involved pediatric patients, 27 were
deemed not relevant and 37 were case series, reviews,
letters or congress proceedings. After a hand search of
the bibliographies, 14 articles met the inclusion criteria
and were considered for this systematic review. All were
retrospective studies.
The main characteristics of patients enrolled are sum-
marized in Table 1. The studies were published in the
three years from 2010 to 2013, with 441 patients en-
rolled from 1987 to 2012. Eight studies were done in the
United States [10,11,20,26,32-34], three in Italy [35-37]
and one each in Sweden, Germany and France [38-40].
Articles identified as relevant: 14 
Retrieved for detailed evaluation, included in qualitative synthesis. 
Added after hand search of bibliographies: 1 
Excluded for study design: 
case series < 10 pts: 26               
review: 6       
letter to Editor/comment: 1  
congress proceedings: 4    
Excluded after screening titles and 
abstracts: 
Pediatric patients: 5    
Not relevant: 27    
Search Strategy 
Electronic literature search in Medline/PubMed and Embase from 2000 to 2014: 82 
Figure 1 Flow chart of the study selection process. Pts, patients.
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bridge: six reported the LAS [10,11,20,32,33,41] and four
the SOFA score [26,35,37,39].
In all the studies, depending on the clinical condi-
tions, either a veno-venous or veno-arterial ECMO was
used [10,11,20,26,32-41]. The strategy during ECMO
bridging was invasive mechanical ventilation in four
studies [33,34,40,41], and spontaneous breathing or
invasive ventilation according to clinical needs in six
studies [20,26,32,35-37]. Unfortunately, four studies
provided no information about the ventilation strategy
during ECMO bridging [10,11,38,39].
The time on ECMO bridging before lung transplant-
ation ranged from a median of 3.2 days [34] to 16 days
[39] (Table 1). Crotti et al., dividing patients according to
whether the waiting time on ECMO was up to 14 days or
longer, observed an ECMO bridging duration of 29.8 ±
11.5 days in patients who received a transplant after wait-
ing more than 14 days on ECMO [35].
Quality of studies
All 14 studies included were retrospective analyses. The
sample size ranged from 11 [37] to 122 [10]. Eight stud-
ies were single-center trials. Seven had no control group
[20,35-40]. Only six studies used the LAS system to
describe the severity of their pre-bridge population[10,11,20,32,33,41]. Across all 14 studies there were sub-
stantial differences in the inclusion criteria for patients,
ECMO program times, and ECMO support technologies
including VV and VA. Because of this, we cannot
exclude a possible confounding role of some important
factors such as diagnosis and comorbidity at the begin-
ning of the bridge. Four studies [10,11,32,37] only
examined patients who were successfully bridged to
transplantation without mentioning patients who had
died while on the waiting list.
Post-LTx complications differed among studies and
were therefore not comparable. For example, six studies
did not report the incidence of primary graft dysfunc-
tion. Over half presented no data on the need for post-
LTx mechanical ventilation (Table 2).
In addition, a learning-curve bias effect cannot be for-
mally excluded in studies enrolling patients over a long
period. Regional differences among studies in organ alloca-
tion policy, institutional differences in the logistic design
and deployment criteria of extracorporeal circuits and
surgeon-specific preferences about organ selection and op-
erative technique also pose limitations for a reliable com-
parison. Given the substantial heterogeneity across studies
we did not attempt a meta-analysis because it would not
have yielded clinically meaningful results; data were de-
scriptively summarized.
Table 1 Characteristics of patients who underwent ECMO bridge to lung transplant and were enrolled in the selected studies
Author, year Patients,
number
Age, years Sex male,
n (%)
Diagnosis Ventilation
strategy
Bridge time, days Severity score
pre-bridge
Mason, 2010 [11] 51 39 ± 22 25 (49%) PF 27%; COPD 19%; CF 12%; PH 9.8%;
sarcoidosis 2%; other 20%
na na LAS 54 ± 21
Bermudez, 2011 [34] 17 40 ± 14 7 (41%) PF 35%; Re-LTx 35%; CF 23%; COPD 6% MV 3.2 (0 to 49) na
Hammainen, 2011 [38] 16 41 ± 8a 7 (58%)a PF 37%a; PH 15%a; CF 8%a; ARDS 8%a; IP 8%a;
PVOD 8%a; BOS 8%a; PGD 8%a
na 12 (1 to 59) na
Shafii, 2012 [41] 19 44 (23 to 60) 10 (53%) IP 68%; CF 16%; PH 16% MV 13 6 ± 5 LAS 87 (64 to 95)
Nosotti, 2012 11 34 ± 13 5 (45%) na Awake 7 MV 4 12.1 ± 14.7 SOFA 4.9 ± 1.4
Javidfar, 2012 [20] 18 34 (22 to 50) 8 (45%) CF 44%; PF 33%; PH 11%; Other 11% Awake 6 11.5 (6 to 18) LAS 93 (90 to 94)
George, 2012 [10] 122 48 ± 16 74 (60%) PF 29.5%; CF 11.5%; COPD 10.7%; PH 2.5%;
other 45,8%
na na LAS 73.9 ± 21.4
Fuehner, 2012 [26] 26 44 (23 to 62) 21 (81%) PF 35%; PH 27%; CF 19%; BOS 12%; sarcoidosis 4% Awake 19 MV 7 9 (1 to 45) SOFA 7 (6 to 12)
Hoopes, 2013 [32] 31 45 ± 15 21 (67%) PF 29%; CF 23%; ILD 13%; ARDS 10%; PVOD 10%;
PH 6%; BOS 3%; IP 3%; CWP 3%
Ambulatory 18
13 VM
11 (2 to 53) LAS >50
Anile, 2013 [36] 12 na na CF 92%; histiocytosis 8% Awake 2 MV 10 6 ± 2.1 na
Toyoda, 2013 [33] 31 46 ± 15a 10 (42%)a PF 33%a; CF 21%a; Re-LTx 13%a; scleroderma 13%a;
bronchiectasis 8%a; COPD 4%a; sarcoidosis 4%a; PH 4%a
MVa 7.1 ± 10 LAS 87 ± 9a
Weig, 2013 [39] 26 36 (30 to 51)a 14 (54%) PF 62%; CF 23%; COPD 4%; Re-LTx 4%; Lung cancer
4%; sarcoidosis 4%
na 16 (8.8 to 25)a SOFA 9 (8.5 to 10.5)a
Crotti, 2013 [35] 25 41 ± 12 na PF 52%; CF 16%; PH 16%; Re-LTx 12%; ARDS 4% Awake 10 MV 15 5.8 ± 4.5 versus 29.8 ± 11.5b SOFA 5.6 ± 1.9
Lafarge, 2013 [40] 36 31 (22 to 48) 19 (53%) CF 56%; PF 30%; other 14% MV 3.5 (2 to 7) na
Data presented in this table refer to patients underwent ECMO support with the intention to bridge to lung transplantation. aTransplanted patients (when data for all enrolled patients are not available; Hammainen et al., all
data; Toyoda, all data; Weig et al., age, ECMO bridge time and SOFA; Anile, diagnosis). ECMO bridge time (days) and the pre-bridge severity score are expressed as mean ± standard deviation or median and range. When no
descriptive cumulative data for the overall population are provided, they are calculated from raw data presented in the original papers. bData refer to patients divided according to waiting time on ECMO: up to 14 days or
longer. Pts, patients; ECMO, extracorporeal membrane oxygenation; PF, pulmonary fibrosis; COPD, chronic obstructive pulmonary disease; CF, cystic fibrosis; PH, Pulmonary hypertension; Re-LTx, Re-lung transplantation;
ARDS, acute respiratory distress syndrome; IP, interstitial pneumonia; PVOD, pulmonary veno-occlusive disease; BOS, bronchiolitis obliterans syndrome; PGD, primary graft dysfunction; ILD, interstitial lung disease; CWP,
coal workers pneumoconiosis; MV, mechanical ventilation; LAS, lung allocation score; SOFA, sequential organ failure assessment; na, not available.
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The mortality rate of patients on ECMO before lung
transplant was reported in ten studies and ranged be-
tween 17% and 50% with multiple organ failure, septic
shock, cardiac failure and bleeding described as the most
frequent causes (Table 2). Interestingly, in the study by
Weig et al. liver failure developed in up to half the pa-
tients who died while awaiting lung transplant [39].
All 14 studies reported the post-transplant one-year sur-
vival rates. In five studies it ranged from 50% to 70%
[10,11,20,39,40], in four 70% to 90% [33,34,36,41] and in
two up to 90% [32,38] (Table 2). When patients were strati-
fied according to the ventilation strategy during ECMO
bridge [37] or according to the ECMO bridge duration [35]
one-year survival was significantly better in spontaneously
breathing patients than mechanically ventilated ones (85%
versus 50%) or when the ECMO bridge duration was
shorter than 14 days (82% versus 29%). Fuehner et al. re-
ported only a six-month survival rate of 80%, for 19
patients on spontaneous breathing and 7 patients on mech-
anical ventilation [26]. Similarly, Hoopes et al. found high
one-year survival in 26 ECMO bridge transplanted patients,
18 of whom were ambulatory at transplantation [32].
Bermudez et al. found the survival rate in patients
who received ECMO support was similar to a control
group that was mechanically ventilated before transplant
(74% versus 78%) [34]. However, they did not report the
LAS score comparing the clinical status of the two
groups. Nonetheless, in patients with similar LAS scores
(54 ± 22 and 54 ± 21) Mason et al. also reported similar
survival rates for those bridged with ECMO and those
with mechanical ventilation (50% and 62%). However,
this was significantly lower than for unsupported pa-
tients (79%) although this group also had lower LAS
scores (40 ± 11) [11].
Despite significantly higher LAS scores (87 ± 9 versus
44 ± 15) Toyoda et al. found comparable survival rates
(74% and 83%) in the ECMO group and in patients who
received the transplant without bridge support [33].
Hoopes et al. reported a post-transplant survival rate of
ECMO patients comparable to or slightly higher than
that of patients with a LAS score higher than 50 trans-
planted without bridge support, from the UNOS data-
base [32]. In contrast, George et al. noted significantly
lower survival in ECMO patients and in mechanically
ventilated patients than in unsupported patients with the
highest LAS quartile (58%, 68% and 81%) [10]. However,
survival of ECMO patients rose significantly, from 30%
in 2005 to 75%, in 2010 [10].
Fuehner et al., applying an awake-ECMO strategy
avoiding intubation and general anesthesia, found sig-
nificantly better survival than with mechanical ventila-
tion (80% versus 50%) [26]. Similarly, Crotti et al.
reported a survival rate of 75% in unsupported ECMOpatients [35]. Although these two studies suggest that
ECMO support as an alternative to invasive mechanical
ventilation seems to achieve better outcomes than when
combined with invasive respiratory assistance, these data
come from very experienced centers and may not be
generalizable. Whether ECMO alone is a better bridging
strategy to lung transplant than invasive mechanical ven-
tilation has yet to be investigated more systematically.
George et al., stratifying the data by age and by diag-
nosis, found that ECMO-bridged patients younger than
62 years had better one-year survival than older patients
(65% versus 38%) as did patients with chronic obstruct-
ive pulmonary disease, while patients bridged to re-lung
transplant had the worst outcomes (84% vs 40%) [10].
Length of stay and ECMO-related complications
The ICU and hospital lengths of stay were reported in six
[20,26,34,37,38,41] and nine studies [10,11,20,26,32,33,
36,37,41] respectively and the medians ranged from 15 to
47 days [20,34] and 22 to 47 days [20] (Table 2). With re-
gard to the ventilation strategy Crotti et al. found that non-
invasive ventilation during ECMO bridge was associated
with significantly shorter ICU and hospital stays than inva-
sive mechanical ventilation (31 ± 19 versus 84 ± 44 days
and 52 ± 28 versus 119 ± 55 days respectively [35]. Similarly,
Nosotti et al. found a shorter mean ICU stay after lung
transplantation in the awake-ECMO group than the mech-
anically ventilated ECMO group, but the difference was not
statistically significant [37].
Postoperative complications in transplanted patients be-
fore discharge from hospital are described in Table 3. The
most frequent were the need for tracheostomy (up to
77%) [38], pulmonary graft dysfunction requiring post-
lung transplant ECMO (54%) [33], pneumonia (52%) [34],
kidney failure treated with renal replacement therapy and
critical illness polyneuropathy/myopathy (up to 70%) [35].
The most frequent causes of death after lung transplant-
ation in ECMO-bridged patients before discharge were
sepsis, multiple organ failure, bleeding and primary graft
dysfunction.
Discussion
This systematic review suggests that the use of ECMO
support as a bridge strategy for patients awaiting lung
transplant is associated with high perioperative morbid-
ity and mortality but achieves acceptable one-year sur-
vival, very similar to that of mechanically ventilated
patients. The initial goal of this systematic review was to
verify the feasibility of meta-analysis of the retrieved
data. However, in view of the wide heterogeneity of the
selected studies we decided to make only a qualitative
summary of the selected literature. The 14 studies in-
cluded are not randomized trials, but retrospective ana-
lyses of case series in which the selection of patients and
Table 2 Outcomes
Author, year Ltx/total
patients, n
Died before Ltx, n (%) Type of
bypass
Survival at
1 yr post-
LTx, %
Length of stay MV, days
post-LTx, days post-LTx
Mason, 2010 [11] 51/51 na na 50% 24 (9 to 55) H na
Bermudez, 2011 [34] 14/17 3 (17%): neurologic dysfunction, thrombosis VV, VA 74% 16 (3 to 40) ICU 12 (2 to 20)
Hammainen, 2011 [38] 13/16 3 (19%): septic MOF VV, VA 92% 22 (3 to 63) ICU na
Shafii, 2012 [41] 14/19 5 (26%): septic MOF 2, DIC 2, anoxic brain injury 1 VV, VA 75% 42 (19 to 175) H 22 (5 to 125)
15 (8 to 42) ICU
Nosotti, 2012 11/11 na VV 87% and 50%b 47.6 ± 21.9 H 27.1 ± 20.7
30 ± 20.4 ICU
Javidfar, 2012 [20] 10/18a 8 (44%): pneumonia 1, MOF 6, CA 1 VV,VA 60% 22 (18 to 33) H na
47 (41 to 52) ICU
George, 2012 [10] 122/122 na na 57.6% 32 (16.5-60) H na
Fuehner, 2012 [26] 20/26 6 (23%): CA 2, septic MOF 4 VV,VA 6-month 80% 38 (20 to 87) H 14 (0 to 64)
18 (1 to 69) ICU
Hoopes, 2013 [32] 31/31 na VA, VV 93% 31 (12 to 86)e H na
Anile, 2013 [36] 7/12 5 (41%) VV, VA 85.7% 29 (15 to 59) H <5
Toyoda, 2013 [33] 24/31 7 (22%) VV,VA 74% 46 median H na
Weig, 2013 [39] 13/26 13 (50%): acute liver failure 7, thoracic bleeding 3, cerebral hemorrhage 1,PE 2 VV,VA 54% na na
Crotti, 2013 [35] 17/25 8 (32%): MOF 3, septic shock 2, cardiogenic shock 2, intestinal ischemia 1 VV,VA 82% and 29%c na 12.2 ± 11.9d
45.3 ± 33.5
Lafarge, 2013 [40] 30/36 6 (17%): GI bleeding 1, DIC 1, cerebral hemorrhage 1, CA 1, septic shock 1, therapeutic limitation 1 VV,VA,CPB 66.5% na na
Data are expressed as mean ± standard deviation or median and range. Mason et al., Nosotti et al., Hoopes et al. and George et al. enrolled transplanted patients. aThree of the eight patients who died had transiently
recovered their baseline function and were weaned from ECMO support; they subsequently died before LTx. bECMO group: 87% awake (7 pts); mechanical ventilation ECMO group: 50% (4 pts); c82% patients on
ECMO bridge <14 days (early): 29% patients on ECMO bridge >14 days (late); d12.2 ± 11.9 days (early group) −45.3 ± 33.5 (late group). eMean (range). LTx, lung transplant; CA, cardiac arrest; MOF, multi-organ failure;
DIC, disseminated intravascular coagulation; GI, gastrointestinal; VV, veno-venous; VA, veno-arterial; CPB, cardiopulmonary by-pass; MV, mechanical ventilation; LOS, length of stay; H, hospital; na, not available.
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Table 3 Complications in patients discharged alive from
hospital and causes of death in hospital after lung
transplant
Complications in patients discharged alive from hospital
▪ Respiratory complications:
? PGD requiring Post-Ltx ECMO 47%[34]; 21%[41]a; 20%[20]a; 54%[33]a
? PGD 72 hours 3rd grade 36%[37]; 15%[39]a; 35%[35]a
? Tracheostomy 41%[34]; 77%[38]a; 64%[41]a; 27%[26]
? Bronchopleura fistula 8%[38]a; 14%[36]a
? Open chest management 50%[41]a; 8%[39]a
? Acute rejection 15%[38]a; 28%[36]a
▪ Acute kidney injury 35%[34]; 12%[35]a
▪ Renal replacement therapy 23%[34]; 38%[38]a; 43%[41]a; 4%[26]; 14%[36]a;
54%[37]; 12%[35]
▪ Infective complications:
? Pneumonia 52%[34]
? Sepsis 23%[34]; 19%[26]; 14%[36]a
▪ Hemorrhagic complications:
? GI bleeding 5%[34]
? Bleeding from femoral artery 5%[34]
? Re-op. for bleeding 15%[38]a; 29%[41]a; 36%[37]; 28%[36]a; 15%[39]a
? Hemorrhage 31%[26]; 35%[35]a
? Massive hemoptysis 15%[26]
▪ Neurological complications:
? Cerebral hemorrhage 5%[34]
? Stroke 8%[38]a
? Ischemia thoracic spinal cord 3%[32]
? CIP/CIM 31%[38]a; 64%[37]; 70%[35]a
▪ Digital ischemia 17%[34]; 14%[36]a
Causes of death in hospital after LTx
▪ MOF 6%[34]; 15%[26]; 7%[40]a
▪ Sepsis 18%[34]; 14%[41]a; 10%[40]a
▪ Acute colonic rupture 8%[38]a
▪ Cardiogenic shock 6%[34]
▪ Cardiac arrest 10%[40]a
▪ Bleeding 9%[37]; 31%[39]a; 3%[40]a
▪ Neurological event 3%[32]
▪ Lung cancer 5%[26]
▪ Bronchopleural fistula 3%[40]a
▪ PGD 31%[39]a
▪ Open chest treatment 23%[39]a
▪ Other 18%[35]a
a percentages of transplanted patients: Shafii et al., Hammainen et al., Javidfar
et al., Toyoda et al., Crotti et al., Anile et al., Lafarge et al., Weig et al.. When
the percentages of complications were not available, complications referring
to the overall enrolled population are reported.
ECMO, Extracorporeal membrane oxygenation; Post-LTx, Post-lung transplantation;
PGD, Primary graft dysfunction; GI, Gastrointestinal; MOF, Multi-organ failure;
Re-op., Re-operation; CIP/CIM, Critical illness polyneuropathy/critical illness
myopathy.
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not homogeneous, thus possibly affecting the efficacy of
the treatment and certainly preventing the results being
evaluated in a meta-analysis.
Lung transplantation is the only option for patients
with end-stage lung failure. However, organ supply is
grossly inadequate compared to the large numbers of
patients awaiting transplant, so mortality in the waiting
list is still very high [11]. In this setting, mechanical ven-
tilation and ECMO are the only supportive strategies
available to prolong these patients’ lives, increasing their
chances of receiving suitable organs.
Although the main benefit of mechanical ventilation is to
improve gas exchange [12], it can in fact open the way to
pulmonary infection, sepsis and muscle atrophy, prolonging
weaning after lung transplant and making it difficult
[11,42,43]. ECMO, on the other hand, could potentially
provide adequate respiratory and hemodynamic support,
with fewer of the side effects of mechanical ventilation in
patients awaiting lung transplant, offering an alternative
bridging strategy [7,13,19,20,22,44]. However, many trans-
plant centers still consider ECMO a contraindication to
lung transplant given the mixed outcomes in patients trans-
planted from ECMO [6]. This systematic review found that
ECMO-bridged patients had satisfactory post-transplant
survival, similar to patients bridged with mechanical venti-
lation. ECMO has helped to save numerous high-risk trans-
plant candidates with otherwise acutely lethal conditions.
Proper patient selection for ECMO is clearly essential for
a good long-term outcome. In the studies reviewed here,
ECMO was not considered suitable for patients with sepsis,
neurologic impairment, profound malnutrition [41] or
severe graft dysfunction after lung transplantation [33],
whereas advanced age (>50 years) was not a contraindica-
tion [41]. The clinical conditions of patients supported with
pre-transplant ECMO are usually more critical than those
of the population awaiting lung transplant and this may
have a negative influence on their overall outcome [16].
However, this systematic review found that at least in se-
lected reports the post-transplant outcome of ECMO-
bridged patients was comparable to recipients who did not
receive pre-transplant support. Any excessive reduction of
the post-transplant survival rate of ECMO-bridged recipi-
ents would obviously defeat the principle of allocating
transplantable lungs on the basis not only of the severity of
their clinical condition, but also the potential long-term
benefit. The definition of clinical parameters predicting sur-
vival for ECMO-bridged patients would certainly help clar-
ify this problematic question [22,45].
In most of the studies reviewed patients bridged with
ECMO were also supported with mechanical ventilation,
thus combining two invasive means of respiratory sup-
port, each with potentially harmful side effects. Recent
reports do suggest that invasive mechanical ventilation
Chiumello et al. Critical Care  (2015) 19:19 Page 8 of 10may still be considered an effective bridge. Mason et al.
showed that the unadjusted post-transplant survival at
one year was 62% for recipients bridged with mechanical
ventilation, 50% for those bridged with ECMO, and 79%
for unsupported patients [11]. Vermeijden et al. com-
pared the outcomes of 13 lung transplant recipients
bridged with invasive mechanical ventilation with 70
controls who received no pre-transplant support [46].
Interestingly, the two groups had similar post-transplant
survival and incidence of primary graft dysfunction.
To further improve the outcome for ECMO-bridged pa-
tients, therefore, it has been proposed that non-invasive
ventilation should be used rather than invasive mechanical
ventilation. This could minimize the muscular decondi-
tioning and ventilator-associated morbidity [42,47-49].
Furthermore, the possibility of keeping patients awake
could avoid the hemodynamic consequences of general
anesthesia and positive-pressure ventilation, especially in
those with pulmonary hypertension. The study that en-
rolled patients bridged to transplant with ECMO as an al-
ternative to invasive mechanical ventilation did in fact
find significantly better six-month survival with ECMO
than with mechanical ventilation (62% versus 35%) [26];
this suggests that preserving spontaneous breathing may
keep patients in a better condition, with fewer of the
drawbacks of mechanical ventilation.
Among the factors that can affect post-transplant out-
come in patients bridged with ECMO, the most frequent
are the duration of the bridge and the timing of the lung
transplant [6]. Although patients can tolerate ECMO for
long periods [34,50,51], any extra waiting time may sig-
nificantly increase mortality [35]. Crotti et al. showed
that patients who received a lung transplant after waiting
more than 14 days had significantly higher rates of mor-
tality and morbidity. ECMO-bridged patients should
therefore be routinely re-assessed to make sure there are
no exclusion criteria for lung transplantation, in order to
optimize outcomes and avoid futile transplants [16].
The incidence of complications in ECMO patients
awaiting lung transplant was similar to those previously
reported in patients receiving ECMO for acute respira-
tory or cardiogenic shock [52]. It was not possible to
compare the ICU and hospital lengths of stay for ECMO
and non-ECMO patients because most of the studies
gave no figures for the control group. Only two studies
reported a shorter hospital stay for patients receiving
awake-ECMO than for those given mechanical ventila-
tion [26,35].
These observations suggest that ECMO might make it
easier to optimize the clinical conditions of transplant
candidates, mainly for more active participation in the
activities of daily living, including ambulation, despite
their critical respiratory illness. However, the length of
stay depends on many factors, such as hospital mortality,which are not necessarily directly linked to support with
ECMO or mechanical ventilation.
Limitations
The present systematic review has several limitations.
First, the studies included are not controlled or random-
ized trials but retrospective analyses of case series, with
broad heterogeneity. Clearly, observational studies rarely
provide sufficiently robust evidence to recommend
changes to clinical practice or health policy decision-
making. However, they are the only ones that provide
any useful evidence for certain topics [31].
Second, the ventilatory strategy of the patients on
ECMO bridging is not described (in terms of end-
expiratory positive pressure, tidal volume, inspiratory
pressure). Third, indications, type and duration of
ECMO bridging differed among studies and some pa-
tients may have been described twice because they were
reported in different studies [10,11,33,34,41]. Fourth, al-
though we confined our literature search to the year
2000 onward because subsequent important advances
were made in the technology for ECMO devices and
mechanical ventilation recommendations that could
have mixed up the results, three studies [11,34,36] en-
rolled patients before this period. Fifth, other extracor-
poreal life support strategies, potentially more easily
manageable than ECMO, such as the artero-venous low
flow extracorporeal carbon dioxide removal [53], the
pulmonary artery-left atrium para-corporeal circuit con-
figuration [54], and the minimally invasive low blood
flow carbon dioxide removal systems [55], have been
used as bridge to lung transplantation, but were ex-
cluded from this systematic review. The continuous
technological advancement in the field of extracorporeal
life support provides progressively more innovative de-
vices, with the purpose to better suit specific patient
populations. However, the notable difference of these
newer strategies from ECMO in terms of management,
complexity, and contribution to gas exchange, suggest
they should be considered as a separate issue.
Conclusions
Since its first application as a bridge to lung transplant-
ation in patients with decompensating acute respiratory
failure, ECMO support has gradually been used more fre-
quently not only as salvage therapy, but also as a very
promising alternative bridging strategy to mechanical ven-
tilation, allowing more physiological respiratory assistance.
However, given the quality and the wide heterogeneity
among studies in this complex field, current clinical evi-
dence does not permit any firm conclusions on the effi-
cacy of ECMO as a bridge to lung transplantation in
addition, or as an alternative to mechanical ventilation,
and further prospective, more systematic multicenter trials
Chiumello et al. Critical Care  (2015) 19:19 Page 9 of 10are awaited. Future studies should ideally consider ECMO
as part of a global algorithm of care for patients with end-
stage lung disease, aiming at keeping them eligible for
transplant despite refractoriness to maximal medical ther-
apy, rather than just as an isolated means of respiratory
support.Key messages
 Patients awaiting lung transplant are at high risk of
death
 Mechanical ventilation can be required in end-stage
severe acute respiratory failure
 ECMO support has been proposed as an alternative
bridging strategy to mechanical ventilation
 ECMO support may provide acceptable one-year
survival
 ECMO support should be part of a global algorithm
of care for these patients
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